Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of ($0.08), $0.09 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $53.2 million versus the consensus estimate of $51.23 million.

GUIDANCE:

Vanda Pharmaceuticals sees FY2025 revenue of $210-250 million, versus the consensus of $284.9 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.